

YaleNewHaven**Health**
Smilow Cancer Hospital

333 Cedar Street
PO Box 208058
New Haven, CT 06520-8058

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

NON-PROFIT ORG.
U.S. POSTAGE
PAID
NEW HAVEN, CT
PERMIT #526

Chênevert Family Brain Tumor Center
35 Park Street, 8th floor
New Haven, CT 06511
203.200.1638
smilowcancerhospital.org

Neuro-Oncologist, Dr. Sylvia Kurz, Joins Chênevert Family Brain Tumor Center



Sylvia Kurz, MD, PhD
Associate Professor of Neurology (Neuro-Oncology)

Appointments:
203.200.1638

Email:
sylvia.kurz@yale.edu

Location:
Chênevert Family
Brain Tumor Center
35 Park Street, 8th floor
New Haven, CT 06511

Sylvia Kurz, MD, PhD, has been named an Associate Professor of Neurology (Neuro-Oncology) and cares for patients as part of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kurz is an internationally acclaimed neuro-oncologist and received both her MD and PhD at Ludwig-Maximilians-University in Munich, Germany. She then completed a residency at University Hospitals Case Medical Center followed by a fellowship in Neuro-Oncology and Immunology at Massachusetts General Hospital/Dana-Farber Cancer Institute/Brigham and Women's Hospital. She was an Assistant Professor in the Departments of Medicine and Neurology and Interim Director of the Neuro-Oncology

Program at Perlmutter Cancer Center prior to returning to Germany where she was a Neuro-Oncologist at the Institute for Neurology and Interdisciplinary Neuro-Oncology at the University Hospital Tübingen before joining Yale.

Dr. Kurz cares for patients with brain tumors as well as those who have immunotherapy-related side effects or pain resulting from cancer treatment-related nerve damage. She conducts translational and clinical research on brain tumors and is a co-investigator on various clinical trials, including several immunotherapy trials. In addition, her research focuses on developing new and more effective treatment options for people with progressive and therapy-resistant intracranial meningiomas.